ArticleEuropean journal of translational myology2022
Pharmacological treatment of presbyopia: A systematic review.
Article in European journal of translational myology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Efficacy and safety of pilocarpine for the treatment of presbyopia: a systematic review and meta‑analysis of randomized controlled trials.Scientific reports · 2026Pooled it
- The effects of topical nepafenac on pupillary dynamics in early postoperative period following uneventful cataract surgery: a prospective randomized study.International ophthalmology · 2025Trial
- Extract fromNutrients · 2024Trial
- Combination Low-Dose Pilocarpine/Diclofenac Sodium and Pilocarpine Alone for Presbyopia: Results of a Randomized Phase 2b Clinical Trial.Clinical ophthalmology (Auckland, N.Z.) · 2024Trial
- Therapeutic Value and Optical Performance of Small-Aperture Intraocular Implants: A Systematic Review.Annals of biomedical engineering · 2026Review
- Beyond glasses: FDA approval of VIZZ (aceclidine) transforming presbyopia management.Annals of medicine and surgery (2012) · 2026Article
- The Science of Pseudoaccommodation and Its Therapeutic Potential.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Current Trends in Presbyopia Correction-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Pharmacological Modulation of Pupil Size in Presbyopia: Optical Modeling and Clinical Implications.Journal of clinical medicine · 2025Article
- Improvement of Presbyopia, Dry Eye, Intraocular Pressure, and Near Vision Through Cassiae Tea Consumption.Medicina (Kaunas, Lithuania) · 2024Article
- Non-Steroidal Anti-Inflammatory Drugs Administered Intra-Articularly in Temporomandibular Joint Disorders: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Correction of presbyopia using 0.5% pilocarpine eye drops among Indians.Bioinformation · 2024Article
- Estimation of the full shape of the crystalline lens from OCT: validation using stretched donor lenses.Biomedical optics express · 2023Article
- Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to identify the efficacy of drug agents for pharmacological Treatment of Presbyopia. Published research papers were reviewed using the relevant terms in PubMed, Science direct, Google scholar, Medline, Google patent, Ovid, Cochrane Database of Systematic Reviews, Scopus. In the initial search, 2270 records were obtained. By removing duplicate articles and all articles that did not meet the inclusion criteria or were inappropriate due to indirect relevance to the subject, 44 studies were selected. It should be noted that all studies had inclusion criteria. There are a number of topical pharmacological agents available for treating presbyopia such as FOV Tears and PresbiDrop. They consist of parasympathetic agent and non-steroidal anti-inflammatory drugs (NSAIDs), to contract the ciliary and pupil muscle and restore the accommodation. Another example of topical pharmacological agent is EV06. It is a lens-softening eye drop which can affect the rigid lens in presbyopia. Currently there is no pharmacological agent available to treat presbyopia. Although there are limited number of peer-reviewed articles available, the outcome for future agents under investigation are promising.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.